These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 24570176)

  • 1. Mosaic RNA phage VLPs carrying domain III of the West Nile virus E protein.
    Cielens I; Jackevica L; Strods A; Kazaks A; Ose V; Bogans J; Pumpens P; Renhofa R
    Mol Biotechnol; 2014 May; 56(5):459-69. PubMed ID: 24570176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel platform for virus-like particle-display of flaviviral envelope domain III: induction of Dengue and West Nile virus neutralizing antibodies.
    Chua AJ; Vituret C; Tan ML; Gonzalez G; Boulanger P; Ng ML; Hong SS
    Virol J; 2013 Apr; 10():129. PubMed ID: 23617954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A VLP-based vaccine targeting domain III of the West Nile virus E protein protects from lethal infection in mice.
    Spohn G; Jennings GT; Martina BE; Keller I; Beck M; Pumpens P; Osterhaus AD; Bachmann MF
    Virol J; 2010 Jul; 7():146. PubMed ID: 20604940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunization of flavivirus West Nile recombinant envelope domain III protein induced specific immune response and protection against West Nile virus infection.
    Chu JH; Chiang CC; Ng ML
    J Immunol; 2007 Mar; 178(5):2699-705. PubMed ID: 17312111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunodominance and functional activities of antibody responses to inactivated West Nile virus and recombinant subunit vaccines in mice.
    Zlatkovic J; Stiasny K; Heinz FX
    J Virol; 2011 Mar; 85(5):1994-2003. PubMed ID: 21147919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A plant-produced vaccine protects mice against lethal West Nile virus infection without enhancing Zika or dengue virus infectivity.
    Lai H; Paul AM; Sun H; He J; Yang M; Bai F; Chen Q
    Vaccine; 2018 Mar; 36(14):1846-1852. PubMed ID: 29490880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity of a West Nile virus DIII-cholera toxin A2/B chimera after intranasal delivery.
    Tinker JK; Yan J; Knippel RJ; Panayiotou P; Cornell KA
    Toxins (Basel); 2014 Apr; 6(4):1397-418. PubMed ID: 24759174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancement of anti-DIII antibodies by the C3d derivative P28 results in lower viral titers and augments protection in mice.
    Dunn MD; Rossi SL; Carter DM; Vogt MR; Mehlhop E; Diamond MS; Ross TM
    Virol J; 2010 May; 7():95. PubMed ID: 20462412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A recombinant fusion protein consisting of West Nile virus envelope domain III fused in-frame with equine CD40 ligand induces antiviral immune responses in horses.
    Liu SA; Haque M; Stanfield B; Andrews FM; Roy AA; Kousoulas KG
    Vet Microbiol; 2017 Jan; 198():51-58. PubMed ID: 28062007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A DNA vaccine encoding the E protein of West Nile virus is protective and can be boosted by recombinant domain DIII.
    Schneeweiss A; Chabierski S; Salomo M; Delaroque N; Al-Robaiy S; Grunwald T; Bürki K; Liebert UG; Ulbert S
    Vaccine; 2011 Aug; 29(37):6352-7. PubMed ID: 21596075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of Virus-Like-Particle Vaccine and Reporter Assay for Zika Virus.
    Garg H; Sedano M; Plata G; Punke EB; Joshi A
    J Virol; 2017 Oct; 91(20):. PubMed ID: 28794019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural and antigenic investigation of Usutu virus envelope protein domain III.
    Josephine Schoenenwald AK; Pletzer M; Skern T
    Virology; 2020 Dec; 551():46-57. PubMed ID: 33011522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a synthetic nanoparticle vaccine presenting the HIV-1 envelope glycoprotein.
    Ximba P; Chapman R; Meyers A; Margolin E; van Diepen MT; Sander AF; Woodward J; Moore PL; Williamson AL; Rybicki EP
    Nanotechnology; 2022 Sep; 33(48):. PubMed ID: 35882111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibodies against refolded recombinant envelope protein (domain III) of Japanese encephalitis virus inhibit the JEV infection to Porcine Stable Kidney cells.
    Verma SK; Gupta N; Pattnaik P; Babu JP; Rao PV; Kumar S
    Protein Pept Lett; 2009; 16(11):1334-41. PubMed ID: 20001924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA-immunisation with dengue virus E protein domains I/II, but not domain III, enhances Zika, West Nile and Yellow Fever virus infection.
    Slon Campos JL; Poggianella M; Marchese S; Mossenta M; Rana J; Arnoldi F; Bestagno M; Burrone OR
    PLoS One; 2017; 12(7):e0181734. PubMed ID: 28742857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of epitope-specific neutralizing antibodies against West Nile virus.
    Oliphant T; Nybakken GE; Austin SK; Xu Q; Bramson J; Loeb M; Throsby M; Fremont DH; Pierson TC; Diamond MS
    J Virol; 2007 Nov; 81(21):11828-39. PubMed ID: 17715236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and efficacy of two types of West Nile virus-like particles different in size and maturation as a second-generation vaccine candidate.
    Ohtaki N; Takahashi H; Kaneko K; Gomi Y; Ishikawa T; Higashi Y; Kurata T; Sata T; Kojima A
    Vaccine; 2010 Sep; 28(40):6588-96. PubMed ID: 20678586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coimmunization with an optimized IL15 plasmid adjuvant enhances humoral immunity via stimulating B cells induced by genetically engineered DNA vaccines expressing consensus JEV and WNV E DIII.
    Ramanathan MP; Kutzler MA; Kuo YC; Yan J; Liu H; Shah V; Bawa A; Selling B; Sardesai NY; Kim JJ; Weiner DB
    Vaccine; 2009 Jul; 27(32):4370-80. PubMed ID: 19497647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recovery of West Nile Virus Envelope Protein Domain III Chimeras with Altered Antigenicity and Mouse Virulence.
    McAuley AJ; Torres M; Plante JA; Huang CY; Bente DA; Beasley DWC
    J Virol; 2016 May; 90(9):4757-4770. PubMed ID: 26912625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Envelope-Modified Tetravalent Dengue Virus-Like-Particle Vaccine Has Implications for Flavivirus Vaccine Design.
    Urakami A; Ngwe Tun MM; Moi ML; Sakurai A; Ishikawa M; Kuno S; Ueno R; Morita K; Akahata W
    J Virol; 2017 Dec; 91(23):. PubMed ID: 28956764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.